TherapeuticsMD, Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
TXMD$1.74+3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(Unaudited - in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net income (loss) | $95 | $(653) |
| Less: Loss from discontinued operations, net of taxes | (8) | (17) |
| Net income (loss) from continuing operations | 103 | (636) |
| Adjustments to reconcile net income (loss) to net cash provided by continuing operating activities: | ||
| Depreciation and amortization | 94 | 95 |
| Write-off patents | — | 88 |
| Share-based compensation costs | 2 | 23 |
| Amortization of right of use assets | 231 | 154 |
| Changes in operating assets and liabilities: | ||
| Other assets | 881 | 502 |
| Prepaid and other current assets | (196) | 433 |
| Accounts payable | (340) | (82) |
| Accrued expenses and other current liabilities | 434 | 274 |
| Lease liabilities | (266) | (203) |
| Other non-current liabilities | 1 | 51 |
| Total adjustments | 841 | 1,335 |
| Net cash provided by continuing operating activities | 944 | 699 |
| Discontinued operations: | ||
| Net cash used in operating activities | (8) | (13) |
| Net cash used in discontinued operations | (8) | (13) |
| Net increase in cash | 936 | 686 |
| Cash and cash equivalents - continuing operations, beginning of period | 7,483 | 5,059 |
| Total cash and cash equivalents, end of period | $8,419 | $5,745 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.